A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Insulin 9 endocrinologydiseasesdrugs
Insulin Aspart 2 endocrinologydiseasesdrugs
diabetes mellitus 12 endocrinologydiseases
type 1 diabetes mellitus 10 endocrinologydiseases
type 2 diabetes mellitus 2 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 44 Title: Clinical PharmacokineticsA Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical
Insulin 61 Title: Clinical PharmacokineticsA Review of Insulin Degludec/ Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical UseHanne HaahrEdmond
Insulin 305 HeisePublication date (epub): 10/2016Publication date (pmc-release): 10/2016Publication date (ppub): /2017Abstract Insulin degludec/insulin aspart (IDegAsp; 70 % IDeg and 30 % IAsp) is a soluble combination of two individual
Insulin 2230 that can offer both basal and mealtime insulin coverage in one injection in patients with diabetes. Insulin degludec/insulin aspart (IDegAsp; 70 % IDeg and 30 % IAsp) provides rapid onset and peak glucose-lowering
Insulin 4237 sustained and stable basal insulin coverage together with an effective mealtime bolus dose in one injection. Insulin degludec/insulin aspart (IDegAsp) is the first soluble combination of two different insulin analogues
Insulin 5257 properties of IDegAsp in the context of the findings from the IDegAsp clinical therapeutic studies. Insulin Formulations to Provide Both Basal and Mealtime CoverageLimitations of Current Premixed Insulin FormulationsCurrent
Insulin 5353 studies.Insulin Formulations to Provide Both Basal and Mealtime CoverageLimitations of Current Premixed Insulin FormulationsCurrent premixed insulin formulations include biphasic human insulin, biphasic insulin aspart
Insulin 7278 with basal-plus and basal-bolus regimens [[26]–[28]].Challenges of Combining a Basal and a Bolus Insulin in a Single FormulationThe ideal way of providing basal and mealtime insulin coverage in one injection
Insulin 16787 CI 0.66–1.13) included 1.00 [[10], [45]].Glucose-Lowering Effect of IDegAsp Compared with Biphasic Insulin Aspart 30 (BIAsp 30)The single-dose glucose-lowering effect profiles have been compared between IDegAsp
Insulin Aspart 61 Title: Clinical PharmacokineticsA Review of Insulin Degludec/ Insulin Aspart : Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical UseHanne HaahrEdmond
Insulin Aspart 16787 CI 0.66–1.13) included 1.00 [[10], [45]].Glucose-Lowering Effect of IDegAsp Compared with Biphasic Insulin Aspart 30 (BIAsp 30)The single-dose glucose-lowering effect profiles have been compared between IDegAsp and
Select Disease Character Offset Disease Term Instance
diabetes mellitus 2749 and may also be an alternative to basal-only and basal-bolus therapy.IntroductionPatients with type 2 diabetes mellitus (T2DM) receiving basal insulin who require additional mealtime insulin can intensify treatment either
diabetes mellitus 13749 glucose-lowering effect of the exogenous insulin under investigation [[37], [38]]. Patients with type 1 diabetes mellitus (T1DM) are the optimal population to evaluate the pharmacodynamic characteristics of exogenous insulin
diabetes mellitus 15205 patients with T1DM (modified from Heise et al. [[9]]. IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus As a consequence of the extended duration of action of IDeg, well beyond 24 h in all patients [[41],
diabetes mellitus 16246 al. [[10]]). IDegAsp insulin degludec/insulin aspart, SD single dose, SS steady state, T1DM type 1 diabetes mellitus The results of a dose–response study in patients with T1DM with single doses of IDegAsp (0.4, 0.6 and
diabetes mellitus 18047 30 biphasic insulin aspart 30, IDegAsp insulin degludec/insulin aspart, SD single dose, T1DM type 1 diabetes mellitus As discussed in Sect. 3.2, the steady-state glucose-lowering effect of IDegAsp is greater than after
diabetes mellitus 20148 (modified from Heise et al. [[9]]). BID twice daily, IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus The duration of action of IDegAsp is longer than 30 h as a result of the extended duration of action
diabetes mellitus 28293 T1DM. IAsp insulin aspart, IDeg insulin degludec, IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus Pharmacological Properties of IDegAsp Across Different Patient PopulationsChildren and Adolescents with
diabetes mellitus 29950 adults with T1DM (from Biester et al. [[11]]). IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus It must be emphasised that guidelines from the International Society for Pediatric and Adolescent Diabetes
diabetes mellitus 31852 IDegAsp insulin degludec/insulin aspart, OD once daily, SD single dose, SS steady state, T1DM type 1 diabetes mellitus Brunner et al. used a population pharmacokinetic/pharmacodynamic model to simulate steady-state glucose-lowering
diabetes mellitus 36192 al. [[13]]). IDegAsp insulin degludec/insulin aspart, SD single dose, SS steady state, T1DM type 1 diabetes mellitus Implications of IDegAsp Pharmacological Properties in Clinical UseIDegAsp is the first combination of
diabetes mellitus 39260 aspart, IDeg insulin degludec, IDet insulin detemir, IGlar insulin glargine, od once daily, T1DM type 1 diabetes mellitus , T2DM type 2 diabetes mellitusTable 2Clinical benefits of IDegAsp and their relation to IDegAsp pharmacological
diabetes mellitus 39291 insulin detemir, IGlar insulin glargine, od once daily, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus Table 2Clinical benefits of IDegAsp and their relation to IDegAsp pharmacological propertiesClinical
type 1 diabetes mellitus 13742 the glucose-lowering effect of the exogenous insulin under investigation [[37], [38]]. Patients with type 1 diabetes mellitus (T1DM) are the optimal population to evaluate the pharmacodynamic characteristics of exogenous insulin
type 1 diabetes mellitus 15198 patients with T1DM (modified from Heise et al. [[9]]. IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus As a consequence of the extended duration of action of IDeg, well beyond 24 h in all patients [[41],
type 1 diabetes mellitus 16239 Heise et al. [[10]]). IDegAsp insulin degludec/insulin aspart, SD single dose, SS steady state, T1DM type 1 diabetes mellitus The results of a dose–response study in patients with T1DM with single doses of IDegAsp (0.4, 0.6 and
type 1 diabetes mellitus 18040 BIAsp 30 biphasic insulin aspart 30, IDegAsp insulin degludec/insulin aspart, SD single dose, T1DM type 1 diabetes mellitus As discussed in Sect. 3.2, the steady-state glucose-lowering effect of IDegAsp is greater than after
type 1 diabetes mellitus 20141 (modified from Heise et al. [[9]]). BID twice daily, IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus The duration of action of IDegAsp is longer than 30 h as a result of the extended duration of action
type 1 diabetes mellitus 28286 with T1DM. IAsp insulin aspart, IDeg insulin degludec, IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus Pharmacological Properties of IDegAsp Across Different Patient PopulationsChildren and Adolescents with
type 1 diabetes mellitus 29943 adolescents and adults with T1DM (from Biester et al. [[11]]). IDegAsp insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus It must be emphasised that guidelines from the International Society for Pediatric and Adolescent Diabetes
type 1 diabetes mellitus 31845 daily, IDegAsp insulin degludec/insulin aspart, OD once daily, SD single dose, SS steady state, T1DM type 1 diabetes mellitus Brunner et al. used a population pharmacokinetic/pharmacodynamic model to simulate steady-state glucose-lowering
type 1 diabetes mellitus 36185 Haahr et al. [[13]]). IDegAsp insulin degludec/insulin aspart, SD single dose, SS steady state, T1DM type 1 diabetes mellitus Implications of IDegAsp Pharmacological Properties in Clinical UseIDegAsp is the first combination of
type 1 diabetes mellitus 39253 degludec/insulin aspart, IDeg insulin degludec, IDet insulin detemir, IGlar insulin glargine, od once daily, T1DM type 1 diabetes mellitus , T2DM type 2 diabetes mellitusTable 2Clinical benefits of IDegAsp and their relation to IDegAsp pharmacological
type 2 diabetes mellitus 2742 formulations and may also be an alternative to basal-only and basal-bolus therapy.IntroductionPatients with type 2 diabetes mellitus (T2DM) receiving basal insulin who require additional mealtime insulin can intensify treatment either
type 2 diabetes mellitus 39284 degludec, IDet insulin detemir, IGlar insulin glargine, od once daily, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus Table 2Clinical benefits of IDegAsp and their relation to IDegAsp pharmacological propertiesClinical

You must be authorized to submit a review.